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Abstract 
 
Objective  
To determine a plausible estimate for a test’s performance in a specific target setting using a 
new method for selecting diagnostic test accuracy studies which are applicable to the setting.  
 
Study design 
It is shown how routine data collected on the test positive rate and the prevalence of disease 
for the setting of interest may be used to derive a region of performance for the test in 
receiver operating characteristic (ROC) space. After qualitative appraisal, studies are selected 
based on the probability that their study accuracy estimates arose from parameters lying in 
this ‘applicable region’. Three methods for calculating these probabilities are developed and 
used to tailor the selection of studies for meta-analysis. The Pap test applied to the UK NHS 
cervical screening programme provides a case example. 
 
Results 
The original meta-analysis for the Pap test included 68 studies but at most 17 studies were 
considered applicable to the NHS. For conventional meta-analysis the sensitivity and 
specificity (with 95% confidence intervals) were estimated to be 72.8% (65.8-78.8) and 
75.4% (68.1-81.5) compared with 50.9% (35.8-66.0) and 98.0% (95.4-99.1) from tailored 
meta-analysis using a binomial method for selection. The effect of this is that for a prevalence 
for Cervical Intraepithelial Neoplasia (CIN) 1 of 2.2%, the post-test probability for CIN 1 
increases from 6.2% to 36.6% between the two methods of meta-analysis. 
 
Conclusion 
Tailored meta-analysis provides a method for augmenting study selection based on the 
study’s applicability to a setting. As such the summary estimate is more likely to be plausible 
for a setting and could improve diagnostic prediction in practice. 
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1. Introduction 
Ensuring that study results are applicable in practice or in a particular clinical setting poses a 
challenge to clinicians and policy makers. Yet this may not always be readily appreciated 
particularly when applying the results of diagnostic or screening test studies in practice; we 
shall see in the methods developed here, it is possible for studies to provide estimates of a 
test’s performance which are highly improbable in some settings.  
 
To facilitate diagnosis, the performance of a test is most usefully reported in terms of either 
its sensitivity and specificity or its positive and negative likelihood ratio - the latter two being 
directly derived from the former two [1,2]. The difficulties arise from these being dependent 
on external factors that may change individually or multiply between different settings. 
Variations in the disease prevalence [3,4], the work up of patients with other tests [3], the 
patient spectrum [5,6], and the execution of the test [7,8] may all contribute to differences in 
a test’s performance between different surroundings [9]. Hence, a study of a diagnostic test 
represents a snap shot of its performance within a particular setting, with its own set of 
external factors. 
 
With the potential for these external factors to vary between different settings, it is not 
surprising that heterogeneity is so widespread in diagnostic test accuracy (DTA) reviews and 
meta-analyses [10]. Although meta-analysis has allowed the study of test characteristics 
across a wide range of environments, the summary estimates they provide represent the 
average performance across all studies [11-13] and may not be representative of an individual 
clinical setting. This may be the case even when study selection is confined to a particular 
setting, such as primary care; the resulting summary (average) estimate may still misrepresent 
some individual primary care settings due to heterogeneity in the true test performance across 
settings. 
 
This creates a problem for the current paradigm of evidence-based medicine, which is 
broadly based on ensuring that the best evidence is applied to clinical practice [14]. This 
usually relies upon the existing methods of critical appraisal being effective at identifying 
those studies which are representative of the setting in question. But without details of the 
external factors from both the study and the end user’s population, how can we be sure that 
this is the case? 
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Rather than wholly relying on the effectiveness of critical appraisal to assess 
representativeness of studies, here an alternative method is proposed. For the purpose of 
meta-analysis, it will be demonstrated how basic data collection from the setting where the 
test is being applied may be used to tailor the selection of studies. 
 
2. Method 
The objective is to determine a plausible estimate for a test’s performance in a specific setting 
given the combination of routine data from the setting and evidence from the literature. 
Broadly, the method relies upon first collecting actual data on the test positive rate and 
prevalence from the setting in question and using this to deduce a region of plausible values 
for the sensitivity and false positive rate for the test in the setting. This is then used to aid 
study selection for meta-analysis by comparing the sensitivities and false positive rates of 
studies with this region. This is now discussed more fully below. 
 
2.1Defining a plausible region of performance for the setting 
Although the true performance of a test within a setting may not be known there are 
quantities which may be measured in the practice setting which allow us to define a plausible 
region of performance – called the applicable region for the test from hereon. 
 
 (i) Using the test positive rate as a constraint 
Normally, within practice the test results are unverified since the true diagnosis, established 
by applying a reference standard, is not known at the time of testing [15]. Consequently, the 
numbers of true positives, false positives, false negatives and true negatives are unknown. 
However, these quantities must be non-negative. 
 
In some settings the unverified results of all patients tested in a clinical population are 
known; for instance, the total number of positive test results and the negative test results for a 
particular test threshold may be counted. Importantly these may be used to constrain the 
possible values that the test’s sensitivity, s and false positive rate, f, may take within the 
practice setting. 
 
If we define the test positive rate, r, as the proportion of all those tested who test positive for 
a particular threshold, then from these observations, the following condition may be deduced 
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if  f   s  this implies  f   r and s ≥ r    (1) 
 
Thus, providing the test is able to classify subjects better than a random process, we can 
define the range of possible values that the false positive rate (FPR) and sensitivity may take 
in the (f, s) plane or ROC space (after Receiver Operating Characteristic curve) [16].  
 
If our estimate of r is unbiased and precise (zero standard error), since these are mathematical 
constraints, the effect of imposing them is to make large areas of ROC space mathematically 
impossible. Although such accuracy and precision is unlikely in practice, these inequalities 
still serve to define the applicable region in ROC space representing the feasible values for 
the test’s performance within the setting in question.  
 
The size of the applicable region is determined in part by the precision of our estimate for r, 
since it affects the width of the confidence interval. Figure 1 demonstrates the effect an 
interval estimate for 0.15 ≤ r ≤ 0.3 (bold boundary) has on the shape of the applicable region 
for a point estimate r = 0.225.  The locations of the boundaries are defined by the upper and 
lower limits of the interval. 
 
To summarise, the test positive rate may be derived by counting the number of patients 
testing positive as a proportion of the total number of patients tested within the target setting 
and a confidence interval estimate may be obtained readily from this. As a result, clinicians 
who frequently apply a particular test in practice could feasibly collect their own data to help 
define their own applicable region for the test.  
 
The applicable region for the test may be refined further by incorporating knowledge of the 
prevalence of the target disorder in clinical practice. 
 
(ii) Incorporating knowledge of the local prevalence 
Suppose the prevalence of the target disorder for the setting of interest, p may be estimated, 
then, it follows from the definitions of the prevalence and sensitivity, s (see appendix 1) that  
 
  

s 
r
p

(1 p) f
p       (2) 
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If it was possible to have perfect knowledge for r and p this would constrain the sensitivity 
and false positive rate for the test in clinical practice to a straight line. Although including 
uncertainty in the estimates for r and p widens the applicable region from a straight line to a 
polygonal area, the area is still narrower than when information on the prevalence is not 
included. 
 
Unlike r, it is more difficult to estimate p with both accuracy and precision. The best estimate 
is obtained from verifying (applying the reference standard to) all the patients in the setting, 
and is therefore unavailable. Accurate estimates of p may be obtained from verifying a small 
sub-sample of patients in the setting as a form of calibration, but with an obvious loss in 
precision; such as, taking a swab (reference standard) from a sub-sample of patients when the 
test is a prediction rule for infection. 
 
More usually, estimates of the prevalence are derived from sources outside of the setting and 
so risk being inaccurate for the setting in question. For example, local laboratories may have 
estimates of disease prevalence for the locality. A Bayesian argument could be used where 
the interval estimate is based on belief either from previous test results or where the empirical 
estimate for the prevalence is believed to be potentially biased. Thus, in a Bayesian 
framework, any summary estimate for the test (see 2.3) is conditioned on this interval 
estimate for the prevalence. 
 
In figure 2, the applicable region shown in figure 1 is refined using an interval estimate for 
the prevalence, for 0.05 ≤ p ≤ 0.12. For each (r, p) pair a straight line constraint (labelled 1 to 
4) is generated and these are illustrated for (r=0.15, p=0.12), (r=0.15, p=0.05), (r=0.30, 
p=0.12), (r=0.30, p=0.05), respectively.  
 
The dotted lines for constraints 2 and 3 are used to demonstrate the fact that these constraints 
are surplus or ‘dominated’ by the other two constraints (1, 4). This follows since if the ‘true’ 
sensitivity and FPR for the test is located to the right of 2 it will always lie to the right of 1, 
but not vice versa. Similarly, 3 is surplus when compared with 4. 
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2.2 Study selection based on the applicable region 
In contrast to conventional meta-analysis, where studies are selected on the basis of 
qualitative criteria alone, here we propose to augment this process by selecting only those 
studies which report performances which are compatible with the setting in question. To do 
this requires an appropriate test procedure which incorporates the constraints defining the 
applicable region.  
 
We are interested in only those studies whose ‘true’ sensitivity and FPR are likely to lie in the 
applicable region, so we may ‘tailor’ the selection of studies for meta-analysis to the setting 
in question. The test procedure used for selecting studies is dependent on whether we have 
knowledge of the test positive rate only or knowledge of both the test positive rate and 
prevalence where deriving the applicable region. The two cases are discussed below. 
 
(i) Knowledge of the test positive rate only 
Suppose r is estimated by some confidence interval with a level of significance, α, then we  
know within a classical framework that the parameter (‘true’ value) for the test positive rate, 
μr, will be present in the interval 100(1- α)% of the time in the long run [17]. We will assume 
μr is contained in the interval. This is reasonable if we choose α so there is a high coverage 
probability, and suggest α is no more than 0.01. This will lead to a loss of precision in the 
estimate for r which may be mitigated by ensuring a large sample size. 
 
Let μf , and μs be the parameters for the FPR and sensitivity, respectively for the test in the 
setting of interest. From (2) we have μf μr and μs ≥ μr whenever μf    μs. Since rlcl  μr rucl, 
where rlcl  and rucl  are the lower and upper confidence limits for r, the most extreme value for 
μf  lies on the boundary when μf =rucl. 
 
Similarly, for a study i to be compatible with the setting of interest its parameter μf,i must lie 
in the applicable region. Its maximum permitted value is when it lies on the boundary when 
μf,i =rucl. Thus, for studies lying to the right of this boundary we test whether the study 
estimate for the FPR, ifˆ , arises from a distribution whose parameter μf,i lies on the boundary 
of the applicable region. Since the FPR, fi has a binomial distribution we may calculate the 
probability of fi being equal to or more extreme than the study estimate ifˆ  given that μf,i =rucl. 
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The FPR is constant along the vertical boundary (see figure 1) so we do not need to consider 
the sensitivity of the study when testing hypotheses. 
 
Hence, we suggest the following test procedure (referred to here as the ‘B1 method’) for 
selecting studies: for study i, the null hypothesis H0: μf,i  = rucl  is rejected in favour of the 
alternative hypothesis, H1: μf,i >rucl if the tail area binomial probability P(fi  ≥ ifˆ  )<β for level 
of significance β. Studies are excluded if H0 is rejected. This provides an exact approach 
given the assumption that μr lies in the confidence interval for r. 
 
Note it is possible for studies lying outside of the applicable region to lie closer to the 
horizontal boundary, s = rlcl than the vertical boundary f = rucl. On such occasions we proceed 
as above but test the null hypothesis of H0: μs,i  = rlcl versus the alternative H1: μs,i  < rlcl. 
 
(ii) Knowledge of test positive rate and prevalence 
Although knowledge of the prevalence within a setting does not allow us to make any 
assertions on the sensitivity and FPR for the setting (see appendix 1), in combination with the 
test positive rate we may refine the size of the applicable region for the setting. 
 
Again we know that the parameters μp and μr for the prevalence and test positive rate 
respectively will lie in their 100 (1- α)% confidence intervals, with a coverage probability of 
1- α. If we assume p and r to be independent then the coverage probability for both μp and μr 
being in their respective 95% confidence intervals at the same time is approximately 0.9. 
However, this probability is likely to be higher, since (1) may be derived from assuming p 
and r to be positively correlated [18]. Clearly, this coverage probability is dependent on the 
value of α chosen, but we will assume that μr and μp for the setting actually lie in their 
respective intervals by always choosing α ≤ 0.01.  
 
Our aim is to select only those studies which have parameters for the sensitivity and FPR, 
(μf,i,μs,i) that lie in the applicable region. Other studies, which have (μf,i, μs,i) outside the 
applicable region, are considered implausible for the setting. Consistent with other models we 
will assume that for a single observation from each study i, the sensitivity, si and FPR, fi are 
independent [11,12] and that both have binomial distributions [12]. 
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If a study reports an estimate )sˆ,fˆ( ii which lies in the applicable region we have no grounds 
for excluding it, since based on a single observation the maximum likelihood estimate (MLE) 
[19] for (μf,i, μs,i) must equal )sˆ,fˆ( ii . For studies which report estimates which lie outside of 
the applicable region we derive the MLE (μmax,f,i , μmax,s,i) for potential (μf,i, μs,i) pairs which 
are constrained to lie in the applicable region, (see Appendix 2).   
 
Once (μmax,f,i , μmax,s,i) has been found, we may calculate the tail area probability, Pi of the 
study i producing an estimate (fi  ≥ ifˆ , si  ≥ isˆ ) given a parameter pair (μmax,f,i , μmax,s,i). Hence 
we have the following test procedure, (‘the B2 method’): if we denote the applicable region 
by A, we reject the null hypothesis H0: (μf,i, μs,i)   A in favour of H1: (μf,i, μs,i)   A
c
  if Pi < β, 
where A
c
 is the complement of A (i.e. all points outside of the applicable region), and β is the 
level of significance. The study is excluded if H0 is rejected and this method provides an 
exact approach given the assumptions on μr and μp lying in the respective intervals for r and 
p. 
 
There are other approaches for estimating μmax,f,i and  μmax,s,i based on assuming that the FPR 
and sensitivity for each study have independent but normal distributions.  The estimate for 
μmax,f,i and  μmax,s,i corresponds to the point on the boundary which minimises the ‘statistical 
distance’ called the Mahalanobis distance, 2iD between the boundary and the study estimate 
)sˆ,fˆ( ii [20]. Here
2
iD  has a
2
2 )( distribution [21] and so the critical value for β =0.025 is 
7.38. Thus, the ‘D2 method’ consists of rejecting H0 if 
2
iD  >7.38 for a particular study. This 
approach has the intuitive appeal of studies being selected on the basis of how ‘close’ they 
are to the applicable region. It also has the advantage that a good approximate estimate for 
2
iD may be calculated directly without recourse to sampling the applicable region (and 
therefore needing to write de novo software) as in the case of the B2 approach. However, 
more refined estimates require an iterative approach which is best achieved computationally 
(see appendix 2).  
 
Thus following qualitative appraisal, the process of study selection has two parts, this is 
summarised by the following algorithm (for the B2 method):  
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1. Define region in ROC space for the test in the setting by collecting data from the setting.  
(i). Collect data on test positives and prevalence (if available) to calculate interval 
estimates for r and p. 
(ii). Use upper and lower confidence limits for r and p to define region in ROC space 
according to relations (1) and (2) (see figure 2). 
(iii). Assume the parameters μr and μp are contained in their interval estimates, then 
the parameters for the sensitivity, μs and FPR, μf for the test in the setting are also 
contained in the region – the ‘applicable region’. 
 
2. Exclude those studies which report a sensitivity and FPR that is improbable for the setting. 
(i) For each primary study derive the maximum likelihood estimate (MLE) from all 
potential parameter pairs for the FPR and sensitivity that are constrained to lie in the 
applicable region – in practice the MLE will be on one of the boundaries. 
(ii). Calculate the tail probability of the study estimate for the FPR and sensitivity 
given the MLE of the parameter pair lying on the boundary. 
(iii). Exclude study if tail probability less than level of significance. 
 
Similarly, study selection based on the ‘minimum distance’ (D2) method follows readily with 
few changes to the second part of the algorithm. 
 
2.3 Statistical methods for aggregating the relevant studies 
Once the applicable studies have been identified, they may be aggregated using a bivariate 
random effects model (BRM) as previously described [12]. In effect a ‘tailored’ meta-
analysis is conducted in which the summary estimate of the sensitivity and specificity is 
derived only from studies compatible with the applicable region.  
 
The method is now illustrated by applying it to the Pap test to estimate its sensitivity and 
specificity when used in the NHS. All analyses were made using the statistical software R 
and STATA. 
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3. Results 
3.1 Case example - Screening for Cervical cancer
 
Until 2003 the NHS Cervical Screening programme used the Pap test exclusively for 
screening women for cervical pre-cancerous changes [22]. The target group is women 
between the ages of 25 to 65 years, who between 25 and 49 are invited on a three yearly basis 
for a smear, and five yearly thereafter [23]. Negative smears result in routine recall, whereas 
abnormal smears lead to further investigation [24].  
 
In 1999-2000, the NHS Cervical Screening programme reported that 169,946 smears were 
classed as mild dyskaryosis or worse [25]. Excluding inadequate smears, 3,675,297 smears 
were classed as negative or borderline [25]. To satisfy (2), the sensitivity of the Pap test in the 
NHS programme must be greater than r =169,946/ 3,845,244 = 4.4%. Table 1 shows that 
within the NHS, r has remained relatively constant across all thresholds for a number of years 
[25], suggesting that the Pap test had a consistent level of performance within the programme 
during this period.  
 
We would like to maximise the coverage probability for the parameter, μr without a 
significant loss of precision. In this instance we may vastly exceed the 2.57 standard errors 
for a 99% confidence interval and provide an interval estimate of (4.437-4.447%) to 5 
standard errors with minimal loss of precision. Essentially in the long run with repeated 
sampling, μr would lie outside such a confidence interval only once in 3.5 million [26]. We 
set 4.437% ≤ r ≤ 4.447%. 
 
The applicable region is refined by estimating the disease prevalence at a threshold of CIN 1. 
The prevalence of CIN 1 or greater in the UK may be estimated to be 2.2% (99% CI 2.19-
2.22%) [27]. This is likely to be an underestimate as it based on those who are referred to 
colposcopy clinic and does not include those with negative smears.  We will set a 
conservative range for p to be 0.5% ≤ p ≤10%. 
 
One meta-analysis [28] which evaluated the accuracy of the Pap test included 68 studies at a 
test threshold of Low grade Squamous Intraepithelial Lesion (mild dyskaryosis in the UK 
system) and a reference standard threshold of CIN 1 [28]. The qualitative criteria used for 
selecting studies were: the study evaluated cervical cytology as a screening test; used 
histology or colposcopy as a reference standard; there was less than 3 months between the 
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cytology and the reference standard being applied; and the 2 x 2 table could be completed 
[28]. 
 
Overall in the review, verification bias was a potential issue with 69% of primary studies 
reporting verification of only a selected (non-random) sample of test negatives. Further only a 
quarter of studies reported blinding of the reference standard. Other factors such as patient 
spectrum were also poorly reported [28]. However, it is unclear what the combined effect of 
these was on individual study estimates. 
 
The results of applying the different methods B1, B2 and D
2
 are summarised in table 2. The 
level of significance, β =0.025. As expected when the applicable region is defined by r only 
(B1 method) more studies (17) are included for tailored meta-analysis than when both r and p 
define the region. The D
2
 method excludes one of these studies (16) and the B2 method 
excludes a further four. The difference between D
2
 and B2 is that the former relies upon a 
normal approximation which may not be valid for some studies of small sample size. 
 
Figure 3 illustrate the effects of applying the B2 method to meta-analysis. The dotted lines 
define the applicable region. The bold squares represent 12 studies reporting FPRs which are 
most likely to be compatible with the NHS programme; there was agreement across the three 
methods on these studies.  The transparent triangles lying outside of the applicable region are 
those studies which are incompatible with the NHS. Out of 17 UK-based studies only 3 were 
in the applicable region. It is clear from figure 3 that conventional meta-analysis provides an 
estimate which would be highly improbable in the NHS given the location of the applicable 
region. 
 
The median sample size for the included set of studies was 105, that is, 50% (6/12) of studies 
had a sample size, n ≤ 105. To put this in context, the studies varied in sample size across 
ROC space: 44% (7/16) of studies had a sample size, n ≤ 105 in the region FPR ≤ 0.1, 
compared with 19% (10/52) of studies in the region FPR >0.1. Thus, the sample sizes of the 
included studies did not vary significantly (p=0.39, Fisher’s exact test) from the FPR ≤ 0.1 
region which contains the applicable region. 
 
Confining the meta-analysis to those studies which are in the applicable region has a 
profound effect on the summary estimates of performance for the Pap test. From conventional 
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meta-analysis the sensitivity and specificity are estimated to be 72.8% (95% CI: 65.8-78.8) 
and 75.4% (95% CI: 68.1-81.5) compared with 50.9% (35.8-66.0) and 98.0% (95% CI: 95.4-
99.1) from tailored meta-analysis using the B2 method for selection. The increased specificity 
also accounts for the eight-fold increase in the positive likelihood ratio from 3.0 (95% CI: 
2.4-3.7) to 25.6 (95% 10.1- 65.0) between the conventional and tailored meta-analysis. The 
effect of this is that, for a background prevalence of CIN 1 of 2.2%, the post-test probability 
for CIN 1 increases from 6.2% to 36.6%. 
 
This example provides empirical evidence that basic information on the target setting may be 
required before applying the results of diagnostic test studies to clinical practice. 
 
 
4. Discussion
 
It is the observation that a test’s performance may vary between settings that makes 
determining when performance statistics are actually applicable to a particular setting, 
important.  Within the traditional paradigm, if the diagnostic process is to truly become 
evidence-based, then this is probably one of the most important questions to answer; 
especially, as it affects both primary and secondary research. 
 
When selecting primary studies for a meta-analysis the usual approach is to use qualitative 
criteria to decide on which studies to include. However, if meta-analyses are to produce 
results that are relevant to clinical practice, choosing studies based on qualitative criteria 
alone may be insufficient. In particular, if there is a wide variation in performances across 
different clinical settings, being clear on the target setting seems equally important. While 
this is usually made clear in the review question, the problem in defining the target setting 
qualitatively is that it may not accurately represent which studies are likely to be applicable. 
 
Here, the possibility of using data collected from the target setting has been highlighted and 
how they may be used to introduce greater objectivity to ascertaining a test’s performance in 
a particular setting. As a result it represents a departure from the usual methodology in meta-
analysis by selecting studies on the basis of their results and not on qualitative criteria alone. 
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However, this should be considered in context. In general, when conducting a meta-analysis 
no assumption is made on where the true performance lies and therefore, there is no 
justification in selecting studies based on their individual results. Nonetheless the studies are 
still constrained by mathematical plausibility.  
 
Similar to conventional meta-analysis potentially some of the included studies may report 
estimates which are either biased due to flaws in the primary study design or subject to 
sampling error. Whereas sampling error is largely accommodated by the models, a number of 
study design biases such as verification bias, participant selection bias, incorporation bias and 
reference standard bias are recognised and may lead to both the overstating and understating 
of test accuracy [29, 30, 31]. In principle part of the critical appraisal process should be 
aimed at mitigating these but it is not always possible. 
 
Other setting-specific factors such as differences in patient spectrum, the positioning of the 
test threshold and the way the test is executed by the clinician may also explain some of the 
variation in the reported test accuracies. Changes in patient spectrum may manifest as a 
change in prevalence [5,6], whilst the latter two may be precipitated by changes in prevalence 
between settings [4, 32]. 
 
The difficultly is in being able to distinguish unbiased estimates from biased estimates and 
there seems to be no straight forward way of achieving this. Usually any differences between 
studies are investigated as part of a general exploration of heterogeneity and since this gives 
some indication of the sources of between-study variation, it should always be carried out. 
 
Ideally, if all the relevant sources of variation were known and their individual and combined 
effects quantifiable, the estimate provided by each study could be modified accordingly to 
provide us with an unbiased estimate of the study parameter. Unfortunately, there are often 
multiple drivers to the accuracy of a test reported in a study and due to a lack of study-level 
data and the potential challenges of modelling multiple covariates, their overall combined 
effect on the reported accuracy is, in general, unknown.  
 
Thus, the method developed here represents a pragmatic approach which considers the 
reported estimate at face-value in terms of its compatibility with the intended target setting. 
Providing a meta-analysis for the test in question exists and test data may be collected from 
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the practice setting, decisions on the applicability of the primary studies to the setting may be 
made. This allows us to produce a summary estimate which is at least plausible for the 
setting, something which conventional meta-analysis is not always able to. 
 
There are two obvious roles for tailored meta-analysis in practice. For those diagnostic tests 
that are being applied in routine practice and where meta-analyses are available, there is the 
potential to use tailored meta-analysis to provide plausible estimates for the performance 
within the setting. This could improve diagnostic prediction and management decision-
making. 
 
Another use may be to aid the decision process of whether a particular test should be used at 
all in practice. Before a new diagnostic technology is introduced into practice, there is often 
substantial uncertainty on how it will actually perform in the intended setting and such 
decisions to implement the technology are most often based on appraisals of the literature and 
economic considerations. However, post-implementation there is the opportunity to re-
appraise the decision to introduce the technology. By collecting setting-specific data and 
defining an applicable region, tailored-meta analysis could be used to re-assess the 
performance of the test and see if it is compatible with those estimates made prior to 
implementation. Ultimately this may lead to a decision on disinvestment.  
 
The apparent theoretical advantage of constraining studies to an applicable region, to 
calculate summary estimates, needs to be validated empirically. This could take the form of 
comparing the results of a primary study in the target setting with the results of a tailored 
meta-analysis based on the available studies or alternatively could be done by way of a 
simulation study. The latter has the advantage of allowing other statistical properties of the 
method to be explored. 
 
Limitations of the analysis and potential areas of research 
The foregoing analysis has demonstrated that the summary estimate derived using only those 
studies which lie in the applicable region is at least feasible for the target setting which is not 
always the case for those estimates derived from conventional meta-analysis. Although, this 
follows from the mathematical constraints, uncertainty in the estimates of the test positive 
rate and the prevalence may result in inaccurate boundaries being drawn for the applicable 
region. However, this is minimised by using interval estimates with a high coverage 
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probability. In the case example, our estimate of the test positive rate in the NHS was to five 
standard errors - the sort of significance demanded by particle physicists when confirming the 
existence of the Higgs Boson [26]! 
 
In tailored-meta-analysis studies are included if they are either inside or ‘close enough’ to the 
applicable region that they cannot be confidently excluded. Although it was not the case with 
the Pap test example used earlier, potentially, some studies of small sample sizes which are 
close to the applicable region could be included because uncertainty in the estimate does not 
allow them to be confidently excluded. However, such studies will have less influence on the 
summary estimate which is weighted towards studies with larger sample sizes. 
 
A potential consequence of selecting only those studies lying in the applicable region for 
meta-analysis is that it is feasible there will be none to aggregate. In such instances, it is 
worth considering whether the data used to define r and p for the setting are reliable. If they 
are then it must be concluded that none of the studies accurately represents how the test 
performs within the target setting. 
 
In summary, the foregoing analysis demonstrates the possibility of using quantitative data 
collected from clinical practice to augment the process of study selection by determining 
quantitatively which studies may be applicable to a setting. Such an approach suggests 
tailoring the meta-analysis to include only the applicable studies before deriving summary 
estimates.  
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Appendix 1. Derivation of the applicable region 
 
1.1 Using the test positive rate to define the test performances feasible in practice 
In the unverified population, all that may be known are the test results without the 
corresponding reference standard results. This is represented by the 2 by 2 below, where x 
(the total number tested positive) and y (the total number tested negative) are known and a, b, 
c and d are unknown. We do know that a,b,c,d ≥ 0, otherwise negative numbers of subjects 
are possible. 
  DISEASE  
  Positive Negative Totals 
TEST 
Positive a b x 
Negative c d y 
 Totals a + c b + d x + y 
 
From definitions of sensitivity, s and FPR, f`  
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From re-arranging we have for f ≠ s   
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Now for a  0 consider the 2 possibilities a = 0 and a > 0. Trivially if a = 0 we have s = 0 
   
For a > 0       
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for  f = s   
)yx(
x
f

   
 
Similarly, solving for b, c and d then setting them all >0 we get the following 2 inequalities. 
 
For f ≥ s  we have 
)yx(
x
s

  and   for  f < s we have 
)yx(
x
s

   
 
Thus we have the results 
f < r and s > r  whenever f < s   (1)   
f  r and s  r  whenever f  s    (2) 
where  
)yx(
x
r

  
 
An alternative derivation of (1) may be obtained from assuming that the probability of a test 
positive and the presence of disease are correlated. This approach was used by Kraemer [18] 
to derive (1). Kraemer’s use of the inequality was confined to single primary studies and not 
used to select studies for meta-analysis. 
 
1.2 Incorporating the prevalence of the target disorder 
Suppose the prevalence of the target disorder, p may be estimated, then, from the definition 
of prevalence, p, sensitivity, s and false positive rate f we have 
 
   
s
a
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Since a + b = x  r
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Hence, we have   f
p
)p(
p
r
s


1
    (3) 
 
Comparing (1) and (3) it can be seen that the size of the applicable region is most dependent 
on having precise knowledge of r. Thus, if p is known perfectly and r is not known, (ie 0 ≤ r 
≤ 1) then all values for f and s in ROC space are still possible. It follows from (3) that for a 
fixed value of p, allowing r to vary between 0 and 1 changes only the intercept. This 
produces a plane of parallel lines which covers all values of ROC space. To appreciate this, 
consider the extreme values of f. For f = 0, s has a value r/p, and since 0 ≤ r ≤ 1 this implies 
that  0 ≤ s ≤ (1/p). Hence, s can take on all values between 0 and 1 since (1/p) ≥1.  
 
Similarly, for f = 1, s has a value of  (r/p) –(1-p)/p. For values of 0 ≤ r ≤ 1, this implies  
–(1-p)/p ≤ s ≤ 1. Hence s takes on values between zero and 1 since –(1-p)/p ≤ 0. For f=1, s 
again covers all values between 0 and 1 in ROC space. Thus, without knowledge of r, even 
perfect knowledge of p is unhelpful. 
Appendix 2 - Selection of studies based on the applicable region 
2.1 Binomial B2 method 
In all three methods we make the assumption that the parameters μr and μp for the test positive 
rate, r and prevalence, p, respectively, lie in their corresponding interval estimates. This is 
only reasonable if the level of significance is chosen so that there is a high coverage 
probability. 
 
For a study i, (fi, si) are the FPR and sensitivity, )sˆ,fˆ( ii are the study estimates and (μf,i, μs,i) 
are the study parameters. Also nf,i and ns,i are the total number without and with the target 
disorder. We are interested only in studies which have (μf,i, μs,i) pairs in the applicable region. 
For a study estimate )sˆ,fˆ( ii lying outside of the applicable region, the maximum likelihood 
estimate (MLE) for a (μf,i, μs,i) pair which actually lies in the applicable region must be 
located on the boundary closest to )sˆ,fˆ( ii .  Since si and fi are independent with 
si~Bin(ns,i,μs,i) and fi ~Bin(nf,i, μf,i), respectively, the likelihood function, L(μf,i, μs,i | ii sˆ,fˆ ) for a 
study i is given by 
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where bi and ai are the number of false positives and true positives for study i respectively. 
This is maximised for (μf,i, μs,i) pairs lying on the closest boundary to )sˆ,fˆ( ii and provides   
(μmax,f,i ,μmax,s,i). If this is written in terms of Log (L(μf,i, μs,i | ii sˆ,fˆ )), the maximum likelihood 
estimate may be obtained by finding the real root to a cubic equation. Alternatively, it may be 
found by sampling points on the boundary closest to )sˆ,fˆ( ii and finding the pair (μf,i, μs,i) 
which yields the maximum value for L(μf,i, μs,i | ii sˆ,fˆ ). The latter method was used here. 
 
The tail area probability, P(fi ≥ ifˆ , si ≥ isˆ  | μf,i= μmax,f,i,, μs,i= μmax,s,i) is given by  
 
 




















 

i,sn
iaa
i,smax,i,s
i,fn
ibb
i,fmax,i,fi ),n|a(Bin),n|b(BinP   
 
Studies are rejected if Pi < β for level of significance β, where β was set to 0.025. 
 
 
2.2 Mahalanobis distance, D
2
method 
If we assume si and fi to have independent normal distributions such 
that, ),(N~s i,si,si
2 and ),(N~f i,fi,fi
2  then the Mahalanobis distance, 2iD  for a study 
i, may be written as  
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Unlike the Euclidean distance between points this allows us to weight the variates according 
to the inverse of their individual variances. As such it represents a ‘statistical’ distance 
between points. The optimum (μf,i , μs,i) point on the boundary, that is, the point which 
maximises the probability of a study estimate for a given (μf,i , μs,i), is that which 
minimises 2iD . It is straight forward to show that this corresponds to the MLE for (μf,i , μs,i) 
since si and fi are assumed to have independent normal distributions. 
 
It may be shown that 2iD  is minimised for a point with μf,i  on the boundary when it is given 
by 
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Similarly, μs,i is given by substituting μf,i into  
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Where (r,p) correspond to either (rucl, plcl) or (rlcl, pucl) depending on which boundary we are 
considering. The parameter μf,i is obtained iteratively by first making initial estimates for the 
variances 
i,f
ii
i,f
n
)fˆ(fˆ 

12  and 
i,s
ii
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Once we have our first estimates μs,i and μf,i these are then substituted into the variances 
instead of ifˆ   and isˆ  and the process continued until we have convergence. 
 
Since 2iD here is the sum of two squared standardised normal variables it has an approximate  
2
2 )( distribution. Thus, for level of significance, β =0.025, the critical value is 7.38. Studies 
are excluded if 2iD  >7.38. 
 
Appendix 3 Results of inclusion/ exclusion decisions using the applicable region. 
 
    
Binomial (B1) 
AR (r only) 
Binomial (B2) 
AR (r and p) 
Mahalanobis (D
2
) 
AR (r and p) 
Name Year Sens FPR Probability Decision Probability Decision D
2 
Decision 
Chomet 1987 33.3 20.0 0.20439 Include 0.0059 Exclude 2.97 Include 
Cox 1995 38.0 4.2 0.62166 Include 1.0 Include 0.00 Include 
Davis 1981 69.5 0.0 1.0 Include 1.0 Include 0.00 Include 
Davison 1994 53.3 0.0 1.0 Include 1.0 Include 0.00 Include 
DiBonito 1993 61.0 4.3 0.59327 Include 0.1777 Include 0.04 Include 
Fung 1997 86.6 9.5 0.03428 Include 0.0033 Exclude 6.45 Include 
Giles 1989 81.3 0.0 1.0 Include 1.0 Include 0.00 Include 
Glenthoj 1988 81.6 0.0 1.0 Include 1.0 Include 0.00 Include 
Gonzalez 1996 38.1 12.2 0.03512 Include 0.0030 Exclude 6.20 Include 
Gundersen 1988 15.4 10.0 0.14879 Include 0.0152 Exclude 2.22 Include 
Jones 1987 17.2 2.2 0.95960 Include 0.2166 Include 0.26 Include 
Morrison 1992 83.3 0.0 1.0 Include 1.0 Include 0.00 Include 
Spitzer 1987 18.2 4.8 0.56556 Include 0.1161 Include 0.01 Include 
Stafl 1981 43.8 10.0 0.36701 Include 0.0257 Include 0.80 Include 
Tay 1987 33.3 0.0 1.0 Include 0.5026 Include 0.13 Include 
Wright 1994b 26.7 1.5 0.9993 Include 0.2987 Include 0.08 Include 
Skehan 1990 82.4 82.8 0 Exclude 0 Exclude 0.00 Exclude 
Cox 1992 43.8 7.8 0.0039 Exclude 0.0005 Exclude 10.64 Exclude 
Coibion 1994 22.0 15.0 0.0083 Exclude 0.0007 Exclude 10.76 Exclude 
Naslund 1986 100.0 23.1 0.0182 Exclude 0.0000 Exclude 12.38 Exclude 
Jones 1992 36.6 13.1 0.0057 Exclude 0.0005 Exclude 11.47 Exclude 
Korn 1994 62.9 15.8 0.0064 Exclude 0.0004 Exclude 12.80 Exclude 
Hellberg 1987 88.9 33.3 0.0266 Include 0.0005 Exclude 13.26 Exclude 
Frisch 1994 35.0 27.3 0.0112 Exclude 0.0004 Exclude 14.03 Exclude 
MacCormac 1988 84.6 5.4 0.0024 Exclude 10
-06
 Exclude 19.60 Exclude 
Korn 1994 63.6 26.3 0.0012 Exclude 10
-05
 Exclude 23.30 Exclude 
Garutti 1994 41.7 14.1 10
-05
 Exclude 10
-06
 Exclude 29.84 Exclude 
Kealy 1986 86.0 12.1 10
-06
 Exclude 10
-07
 Exclude 34.14 Exclude 
Del Priore 1995 80.0 25.0 10
-05
 Exclude 10
-06
 Exclude 35.64 Exclude 
Andrews 1989 26.3 12.3 10
-06
 Exclude 10
-08
 Exclude 35.86 Exclude 
Herrington 1995 68.8 38.5 0.0002 Exclude 10
-06
 Exclude 38.51 Exclude 
Tait 1988 74.5 18.4 10
-06
 Exclude 10
-07
 Exclude 39.36 Exclude 
Ferris 1998 37.0 14.5 10
-07
 Exclude 10
-09
 Exclude 45.32 Exclude 
Giles 1988 53.1 14.9 10
-07
 Exclude 10
-09
 Exclude 47.03 Exclude 
Mayeaux 1995 43.8 19.2 10
-08
 Exclude 10
-09
 Exclude 53.87 Exclude 
Singh 1985 75.2 66.7 10
-05
 Exclude 10
-07
 Exclude 59.51 Exclude 
Herrington 1995 68.8 29.7 10
-07
 Exclude 10
-09
 Exclude 60.91 Exclude 
Wheelock 1989 48.1 18.6 10
-10
 Exclude 10
-11
 Exclude 70.51 Exclude 
Parker 1986 74.5 15.4 10
-10
 Exclude 10
-12
 Exclude 72.81 Exclude 
Oyer 1986 75.1 21.0 10
-09
 Exclude 10
-11
 Exclude 75.43 Exclude 
Johansen 1979 90.2 28.3 10
-10
 Exclude 10
-12
 Exclude 91.35 Exclude 
Syrjanen 1987 72.8 17.9 10
-14
 Exclude 10
-16
 Exclude 107 Exclude 
Koonings 1992 79.5 29.0 10
-11
 Exclude 10
-13
 Exclude 109 Exclude 
Chomet 1987 67.0 38.9 10
-10
 Exclude 10
-12
 Exclude 109 Exclude 
Haddad 1988 86.7 56.3 10
-09
 Exclude 10
-11
 Exclude 112 Exclude 
Smith 1987 78.0 41.9 10
-10
 Exclude 10
-12
 Exclude 113 Exclude 
Young 1993 72.0 27.4 10
-12
 Exclude 10
-14
 Exclude 115 Exclude 
Nyirjesy 1972 60.0 50.0 10
-11
 Exclude 10
-13
 Exclude 136 Exclude 
Koonings 1992 69.3 36.4 10
-13
 Exclude 10
-16
 Exclude 144 Exclude 
     
Binomial (B1)  
AR (r only) 
Binomial (B2)  
AR (r and p) 
Mahalanobis (D
2
) 
AR (r and p) 
Name Year Sens FPR Probability Decision Probability Decision D
2 
Decision 
Walker 1986 76.9 46.9 10
-12
 Exclude 10
-14
 Exclude 149 Exclude 
Bolick 1998 85.1 63.6 10
-14
 Exclude 10
-16
 Exclude 200 Exclude 
Lozowski 1982 93.0 50.0 0 Exclude 0 Exclude 219 Exclude 
Germain 1994 66.7 21.0 0 Exclude 0 Exclude 220 Exclude 
Beeby 1993 65.7 21.9 0 Exclude 0 Exclude 288 Exclude 
Baldauf 1995 92.9 68.8 0 Exclude 0 Exclude 347 Exclude 
Maggi 1989 76.9 47.8 0 Exclude 0 Exclude 436 Exclude 
Soutter 1986 83.2 56.9 0 Exclude 0 Exclude 464 Exclude 
Bigrigg 1990 96.4 66.0 0 Exclude 0 Exclude 469 Exclude 
Kwikkel 1986 98.0 91.9 0 Exclude 0 Exclude 744 Exclude 
Rasbridge 1995 86.6 49.7 0 Exclude 0 Exclude 872 Exclude 
Wetrich 1986 81.2 33.1 0 Exclude 0 Exclude 928 Exclude 
Upadhyay 1984 99.6 77.9 0 Exclude 0 Exclude 970 Exclude 
Fahim 1991 85.1 38.0 0 Exclude 0 Exclude 1283 Exclude 
Melnikow 1997 88.6 88.5 0 Exclude 0 Exclude 2075 Exclude 
Melnikow 1997 98.7 88.5 0 Exclude 0 Exclude 2103 Exclude 
Parham 1991 98.5 82.2 0 Exclude 0 Exclude 2500 Exclude 
Soost 1991 86.6 65.3 0 Exclude 0 Exclude 6701 Exclude 
Jones 1996 74.5 25.3 0 Exclude 0 Exclude 6871 Exclude 
 
Data from McCrory et al [28] 
 
Notes: 
Probability = probability of study estimate given parameter pair on the boundary 
Decision = decision to include or exclude study from tailored meta-analysis 
AR = applicable region defined by either r only, or r and p. 
 
A study was excluded if the probability was <0.025. Using the Mahalanobis distance this 
corresponded to a critical value of 7.38 
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Figure 1. Hypothetical example demonstrating how the constraints define the applicable 
region (the bold continuous line).  
 
The bold lines represent the constraint imposed by rlcl ≤ r ≤ rucl, on s and f (inequality (1) in 
text), where rlcl and rucl correspond to the lower and upper confidence limits for r. Here rlcl = 
0.15 and rucl = 0.30. 
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Figure 2. Hypothetical example demonstrating how the constraints define the applicable 
region (the bold continuous trapezium) after including estimates of the test positive rate, r 
and prevalence, p. The outer dashed lines represent the constraint imposed by 0.15 ≤ r ≤ 0.3 
on s and f . The lines represented by 1-4 are the result of imposing equation (2) in addition to 
(1) for 0.05 ≤p ≤ 0.12 and 0.15 ≤ r ≤ 0.3. For example line 1 combines s= (r/p) –((1-p)f/p) for 
(r =rlcl= 0.15, p=pucl = 0.12) and (s≥r and f≤r) for (r= rlcl= 0.15). Lines 2 and 3 are 
dominated by 1 and 4 and are therefore surplus (see text for explanation). 
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Threshold 1999-2000 2000-01 2001-02 2002-03 
borderline 0.0919 0.0900 0.0861 0.0851 
mild 0.0442 0.0431 0.0406 0.0406 
moderate 0.0173 0.0166 0.0158 0.0156 
severe 0.0076 0.0075 0.0071 0.0071 
 
Table 1. The test positive rate, r, for each of the cytology thresholds in the NHS Cervical 
screening programmes over 4 years 
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  AR (r only) AR ( both r and p) 
 All Binomial (B1) Mahalanobis, (D
2
) Binomial (B2) 
Included studies (n) 68 17 16 12 
     
sensitivity 72.8% (65.8-78.8) 52.6% (37.9-66.9) 49.6% (35.4-63.8) 50.9% (35.8-66.0) 
specificity 75.4% (68.1-81.5) 96.0% (93.0-97.8) 96.6% (93.8-98.1) 98.0% (95.4-99.1) 
LR+ 2.96 (2.37-3.68) 13.21 (7.22-24.17) 14.4 (7.4-28.2) 25.6 (10.1-65.0) 
LR- 0.36 (0.30-0.44) 0.49 (0.36-0.67) 0.52 (0.39-0.70) 0.50 (0.36-0.69) 
 
Table 2. Performance characteristics of the Pap test using conventional meta-analysis, the B1 
method, D
2 
method and the B2 method. Note AR = applicable region. 95% confidence 
intervals in brackets. 
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Figure 3. Tailored meta-analysis of the Pap test in the NHS using the B2 method.  
The dotted line represents the applicable region using interval estimates for the test positive 
rate r and prevalence p. The bold squares are the included studies under the B2 method and 
the unfilled triangles are the excluded studies. The grey ‘elliptical region’ represents the 
confidence region (point estimate in centre) using conventional meta-analysis. The black 
ellipse is the associated confidence region enclosing the point estimate for tailored meta-
analysis. 
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